Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2024.01.02
-
VOLUNTARY ANNOUNCEMENT - APPROVAL OF CLINICAL TRIAL FOR INNOVATIVE MEDICINE "TRD205 (AT2R RECEPTOR ANTAGONIST)" TABLET2023.12.27
-
VOLUNTARY ANNOUNCEMENT - COMPLETION OF PATIENT ENROLLMENT IN PHASE III CLINICAL TRIAL OF ANLOTINIB (A CATEGORY I NNOVATIVE DRUG) COMBINED WITH CHEMOTHERAPY IN FIRST-LINE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA2023.12.22
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.12.22
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.12.21
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.12.19
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.12.18
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR MARKETING OF TQG203 “RECOMBINANT HUMAN COAGULATION FACTOR VIIa FOR INJECTION” FILED AND ACCEPTED2023.12.13